Karin Dilger - Concepedia

Author

Karin Dilger

Dr Falk Pharma (Germany)

Also Known As

Karin Dilger

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Dr Falk Pharma (Germany)Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology University of Tübingen Robert Bosch (Germany)Donetsk National Medical University

About

Karin Dilger is an author at Dr Falk Pharma (Germany) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	724
2	Biochemistry	3	3	193
3	Allergy	2	2	54
4	Natural Sciences	1	1	69
5	Cell Biology	1	1	92

Karin Dilger

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis Stephan Miehlke, Petr Hrúz, Michael Vieth, Gut	2015	208
Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary Cirrhosis Wolfgang Hempfling, F Grünhage, Karin Dilger, Hepatology	2003	162
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health Karin Dilger, Simon Hohenester, Ursula Winkler–Budenhofer, Journal of Hepatology UrologyHepatologyBiliary TractMedicineLiver Physiology	2012	113
Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction* Hans-Peter Platten, Eberhard Schweizer, Karin Dilger, Clinical Pharmacology & Therapeutics	1998	100
Identification of Budesonide and Prednisone as Substrates of the Intestinal Drug Efflux Pump P-glycoprotein Karin Dilger, Matthias Schwab, Martin F. Fromm Inflammatory Bowel Diseases Gastrointestinal PharmacologyGlycobiologyGastroenterologyPathologyImmunology	2004	92
Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease A Tromm, Ivan Bunganič, Eva Tomsová, Gastroenterology InflammationAnti-inflammatoryGastrointestinal PharmacologyMedicineGastroenterology	2010	90
Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib Stefanie S. Brenner, Charlotte Herrlinger, Karin Dilger, Clinical Pharmacokinetics Steady-state DispositionMedicineGeneticsCytochrome P450 2C9Pathology	2003	84
Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial Andreas Münch, Johan Bohr, Stephan Miehlke, Gut	2014	83
Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6 Karin Dilger, Bernd Greiner, Martin F. Fromm, Pharmacogenetics Propafenone P.oRifampicin TreatmentCytochrome P4502d6Secondary MetabolitePharmacotherapy	1999	69
Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis Tilo Andus, Andreas Kocjan, Moritz Müser, Inflammatory Bowel Diseases	2010	64

Page 1